Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A13938 | 29679615 | Metabolism | Novel protective role of kallistatin in obesity by limiting adipose tissue low grade inflammation and oxidative stress. | 2018 | Details |
| A13951 | 29673898 | EBioMedicine | Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models. | 2018 | Details |
| A13953 | 29673321 | BMC Gastroenterol | Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis. | 2018 | Details |
| A13961 | 29670908 | Biomed Res Int | Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. | 2018 | Details |
| A13965 | 29666185 | J Biol Chem | Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. | 2018 | Details |
| A13979 | 29660603 | Alcohol | Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis. | 2017 | Details |
| A13981 | 29660324 | Gastroenterology | Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A13982 | 29660233 | Liver Int | Nonalcoholic fatty liver disease is associated with decreased lung function. | 2018 | Details |
| A13983 | 29659559 | Nutrients | Vitamin D and the Liver-Correlation or Cause? | 2018 | Details |
| A13987 | 29656250 | Environ Pollut | Exposure to environmental level phenanthrene induces a NASH-like phenotype in new born rat. | 2018 | Details |
| A13990 | 29655574 | Rev Gastroenterol Mex (Engl Ed) | Current treatment for non-alcoholic fatty liver disease. | 2018 | Details |
| A13996 | 29653100 | Chem Biol Interact | Vitamin D nanoemulsion enhances hepatoprotective effect of conventional vitamin D in rats fed with a high-fat diet. | 2018 | Details |
| A14003 | 29643297 | J Vet Med Sci | Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model. | 2018 | Details |
| A14015 | 29633352 | J Gastroenterol Hepatol | Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. | 2018 | Details |
| A14017 | 29632425 | World J Gastroenterol | Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. | 2018 | Details |
| A14018 | 29631866 | Gastroenterol Hepatol | Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. | 2018 | Details |
| A14024 | 29629626 | Expert Rev Gastroenterol Hepatol | The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review. | 2018 | Details |
| A14025 | 29629490 | Dig Dis Sci | Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage. | 2018 | Details |
| A14029 | 29627620 | Contemp Clin Trials | Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. | 2018 | Details |
| A14045 | 29615085 | Diagn Pathol | Expression patterns of STAT3, ERK and estrogen-receptor α are associated with development and histologic severity of hepatic steatosis: a retrospective study. | 2018 | Details |
| A14047 | 29614799 | Nutrients | Folate and B12 Levels Correlate with Histological Severity in NASH Patients. | 2018 | Details |
| A14050 | 29609501 | Expert Rev Gastroenterol Hepatol | The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. | 2018 | Details |
| A14055 | 29608442 | Eur J Gastroenterol Hepatol | Cognitive assessment of patients with nonalcoholic fatty liver disease. | 2018 | Details |
| A14058 | 29607635 | J Korean Med Sci | Estimated Prevalence of Adolescents with Nonalcoholic Fatty Liver Disease in Korea. | 2018 | Details |
| A14060 | 29607054 | BMJ Open Gastroenterol | Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). | 2018 | Details |
| A14062 | 29604480 | Atherosclerosis | Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. | 2018 | Details |
| A14069 | 29603365 | J Gastroenterol Hepatol | Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? | 2018 | Details |
| A14070 | 29603349 | J Leukoc Biol | Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD. | 2018 | Details |
| A14074 | 29601441 | J Pediatr Gastroenterol Nutr | The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14080 | 29600430 | Hepatol Int | Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. | 2018 | Details |
| A14081 | 29599925 | Oncotarget | A porcine placental extract prevents steatohepatitis by suppressing activation of macrophages and stellate cells in mice. | 2018 | Details |
| A14090 | 29593815 | Arch Med Sci | Preventive effects of total saponins of Panax japonicus on fatty liver fibrosis in mice. | 2016 | Details |
| A14098 | 29588839 | Frontline Gastroenterol | Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. | 2017 | Details |
| A14111 | 29577560 | Liver Int | Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. | 2018 | Details |
| A14112 | 29577364 | Aliment Pharmacol Ther | Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. | 2018 | Details |
| A14114 | 29575516 | Liver Int | Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. | 2018 | Details |
| A14117 | 29575023 | Clin Transplant | Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. | 2018 | Details |
| A14122 | 29574534 | J Gastroenterol | To die or not to die: death signaling in nonalcoholic fatty liver disease. | 2018 | Details |
| A14125 | 29572891 | Hepatology | Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. | 2018 | Details |
| A14129 | 29572095 | J Hepatol | A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. | 2018 | Details |
| A14137 | 29568204 | World J Gastroenterol | Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. | 2018 | Details |
| A14145 | 29564257 | J Family Med Prim Care | Relationship between serum ferritin level and transient elastography findings among patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A14147 | 29564059 | Gastroenterol Hepatol Bed Bench | Is treatment of fatty liver effective on reducing carotid intima media thickness; a cohort study. | 2018 | Details |
| A14153 | 29561981 | Arq Gastroenterol | MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY. | 2018 | Details |
| A14156 | 29560693 | Acta Gastroenterol Belg | Apoptosis and Disease Severity is Associated with Insulin Resistance in Non-alcoholic Fatty Liver Disease. | 2018 | Details |
| A14158 | 29560647 | Acta Gastroenterol Belg | Hepatic complications of bariatric surgery : the reverse side of the coin. | 2018 | Details |
| A14159 | 29558460 | Int J Mol Sci | p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. | 2018 | Details |
| A14171 | 29553485 | J Clin Invest | Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis. | 2018 | Details |
| A14172 | 29552625 | Cell Mol Gastroenterol Hepatol | Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). | 2017 | Details |
| A14176 | 29550812 | Cell Physiol Biochem | Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A14179 | 29549269 | Sci Rep | Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. | 2018 | Details |
| A14180 | 29548345 | BMC Pharmacol Toxicol | A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. | 2018 | Details |
| A14186 | 29544992 | Mol Aspects Med | Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. | 2018 | Details |
| A14203 | 29527255 | World J Hepatol | Glycogenic hepatopathy: A narrative review. | 2018 | Details |
| A14214 | 29523305 | Med Hypotheses | Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. | 2018 | Details |
| A14216 | 29522534 | PLoS One | Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease. | 2018 | Details |
| A14218 | 29519663 | Surg Obes Relat Dis | Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease? | 2017 | Details |
| A14219 | 29519502 | Lancet | NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. | 2018 | Details |
| A14223 | 29517271 | Biomark Med | The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. | 2018 | Details |
| A14225 | 29516226 | Eur J Nutr | Chronic fructose intake does not induce liver steatosis and inflammation in female Sprague-Dawley rats, but causes hypertriglyceridemia related to decreased VLDL receptor expression. | 2018 | Details |
| A14230 | 29514047 | Biochim Biophys Acta Mol Basis Dis | Deletion of NLRX1 increases fatty acid metabolism and prevents diet-induced hepatic steatosis and metabolic syndrome. | 2018 | Details |
| A14237 | 29511346 | Oncogene | Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. | 2018 | Details |
| A14238 | 29510489 | Int J Mol Sci | Divergent Role of Sphingosine 1-Phosphate in Liver Health and Disease. | 2018 | Details |
| A14243 | 29507903 | Hepatol Commun | Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease. | 2018 | Details |
| A14254 | 29503789 | Curr Hepatol Rep | Managing the Burden of Non-NASH NAFLD. | 2017 | Details |
| A14258 | 29499974 | Trends Pharmacol Sci | Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. | 2018 | Details |
| A14265 | 29494209 | Am J Physiol Gastrointest Liver Physiol | Biliverdin reductase and bilirubin in hepatic disease. | 2018 | Details |
| A14266 | 29493856 | Liver Int | Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease. | 2018 | Details |
| A14269 | 29491288 | Intern Med | A Patient with Non-alcoholic Steatohepatitis Complicated by Multiple Myeloma. | 2018 | Details |
| A14275 | 29488482 | Ter Arkh | [Optimization of therapy for hepatobiliary disorders in psoriatic patients]. | 2019 | Details |
| A14282 | 29484189 | Pharmacol Res Perspect | Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. | 2018 | Details |
| A14283 | 29483677 | J Hum Genet | Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. | 2018 | Details |
| A14286 | 29482963 | Nutr Metab Cardiovasc Dis | Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. | 2017 | Details |
| A14287 | 29482933 | Acta Histochem | Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study. | 2018 | Details |
| A14293 | 29479443 | Gastroenterol Rep (Oxf) | Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with non-alcoholic fatty liver disease. | 2017 | Details |
| A14296 | 29477355 | Endocrinol Diabetes Nutr (Engl Ed) | Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes. | 2018 | Details |
| A14302 | 29473277 | Hepatol Res | Formation of p62-positive inclusion body is associated with macrophage polarization in non-alcoholic fatty liver disease. | 2018 | Details |
| A14304 | 29472495 | Drug Metab Dispos | Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14306 | 29471595 | Diabetes Metab Res Rev | Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. | 2018 | Details |
| A14307 | 29471562 | Semin Liver Dis | Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis? | 2018 | Details |
| A14317 | 29469051 | Ann Hepatol | Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse. | 2018 | Details |
| A14326 | 29464178 | Can J Gastroenterol Hepatol | Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assessment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients. | 2017 | Details |
| A14327 | 29463916 | Int J Obes (Lond) | Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. | 2018 | Details |
| A14328 | 29463906 | Nat Rev Gastroenterol Hepatol | Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. | 2018 | Details |
| A14329 | 29463471 | EBioMedicine | IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. | 2018 | Details |
| A14332 | 29463024 | Int J Mol Sci | Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. | 2018 | Details |
| A14337 | 29461236 | Georgian Med News | FEATURES OF EXCRETION OF MELATONIN IN URINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE WITH MANIFESTATIONS OF FIBROSIS AND ITS RELATIONSHIP WITH CERTAIN METABOLIC AND IMMUNOLOGICAL INDICATORS. | 2018 | Details |
| A14339 | 29457838 | Hepatology | Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. | 2018 | Details |
| A14346 | 29454647 | Cell Immunol | Dynamic plasticity of macrophage functions in diseased liver. | 2017 | Details |
| A14349 | 29452601 | Cardiovasc Diabetol | Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. | 2018 | Details |
| A14350 | 29452268 | Clin Gastroenterol Hepatol | High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. | 2018 | Details |
| A14360 | 29448843 | Expert Opin Investig Drugs | Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. | 2018 | Details |
| A14362 | 29446942 | J Med Chem | Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. | 2018 | Details |
| A14364 | 29446106 | Aliment Pharmacol Ther | Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. | 2018 | Details |
| A14370 | 29441440 | Front Med | γδ T cells in liver diseases. | 2018 | Details |
| A14378 | 29438418 | PLoS One | Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet. | 2018 | Details |
| A14380 | 29437160 | Int J Obes (Lond) | Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes. | 2017 | Details |
| A14390 | 29431403 | Am Fam Physician | Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. | 2017 | Details |
| A14394 | 29428719 | Biochem Biophys Res Commun | Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. | 2018 | Details |
| A14397 | 29427497 | Liver Int | Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. | 2018 | Details |